

THE AI STARTUP UNIVERSE: A COMPANY SNAPSHOT



SINCE 2015



LEADERSHIP

KUAN CHEN
FOUNDER & CEO

HUANGSHUOYU
WENG
CTO

YUFENG (MATT) DENG, Ph.D.,
DIRECTOR NORTH AMERICA

TONY GEVO
VP NORTH AMERICA



CLIENTS

300+

Global partner hospitals across Asia, Europe and North America



PARTNERSHIPS



BUSINESS MODEL

OTLF (One Time License Fee or Perpetual License, i.e. one licensing payment up front and support fees starting with year two), **SaaS, Pay-per-exam**



INVESTMENT ROUNDS

TOTAL FUNDING

\$73M

Funding rounds in 2017:

Series A: \$1.8M

Series A: \$7M

Series B: \$17M

Funding rounds in 2018:

Series B: \$47M



BRIEF HISTORY

2015 – **Founded**

2015-2016 – 13 **partner hospitals** installed


2017 – First Chinese firm **awarded** Tokyo Strategic Special Region High-Tech Enterprise Certification

2017 – **North American office** established in Philadelphia


2018 – **US clinical trials & evaluation sites** installed including University of Maryland, Wake Radiology UNC REX Healthcare, Stanford, Quantum Imaging in Harrisburg, Kettering Health Network



AREA OF EXPERTISE/ CURRENT SOLUTIONS:



- Applications targeted at the detection and quantification of lesions in Lung CT, brain hemorrhage, mammo, MSK fracture, bone age and fractures



MODALITIES COVERED



CT, DR, DBT



STEP OF THE RADIOLOGIST JOURNEY




IMAGE PROCESSING, DETECTION, DIAGNOSIS, LABELLING & REPORTING, PATIENT COMMUNICATION



VISION FOR THE FUTURE

Product Development Roadmap:

- Modalities:** Ultrasound
- New application areas:** lymph node detection/diagnosis, multiple detection/diagnosis on a single scan, e.g. using multiple products on a chest CT simultaneously looking for lung nodules, lymph nodes, fractures, etc.



How do you see the future of the AI ecosystem?

AI will continue to gain traction, both clinically and administratively. This will increase both the clinician's efficiency & patient outcomes.

What is your role in it?

Infervision, with its commitment and financial stability, will continue its **leadership** position.

